T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.18% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
Vir Biotechnology
VIR
$1.56B
| $4.5M | ﹤0.01% |
176,539
-273,824
| -61% | -$6.39M |
|
1427
Lamar Advertising Co
LAMR
$15.8B
| $4.48M | ﹤0.01% |
50,911
+4,870
| +11% | +$494K |
|
1428
MoonLake Immunotherapeutics
MLTX
$1.4B
| $4.44M | ﹤0.01% |
870,524
+304,333
| +54% | +$1.91M |
|
1429
NNN REIT
NNN
$8.83B
| $4.42M | ﹤0.01% |
102,690
-7,652
| -7% | -$337K |
|
1430
Cleveland-Cliffs
CLF
$6.79B
| $4.38M | ﹤0.01% |
284,851
-2,375,283
| -89% | -$56.8M |
|
|
COHR
1431
DELISTED
Coherent Inc
COHR
| $4.36M | ﹤0.01% |
16,368
+1,507
| +10% | +$404K |
|
|
AKRO
1432
DELISTED
Akero Therapeutics
AKRO
| $4.3M | ﹤0.01% |
455,302
-62
| -0% | -$646 |
|
1433
Genius Sports
GENI
$2.33B
| $4.29M | ﹤0.01% |
1,906,493
| – | – |
|
1434
Rocket Lab Corp
RKLB
$51.3B
| $4.28M | ﹤0.01% |
+1,129,642
| New | +$6.65M |
|
1435
Reinsurance Group of America
RGA
$16.3B
| $4.28M | ﹤0.01% |
36,473
+435
| +1% | +$50.5K |
|
1436
Wyndham Hotels & Resorts
WH
$5.46B
| $4.27M | ﹤0.01% |
65,016
-3,310
| -5% | -$261K |
|
1437
HNI Corp
HNI
$3.53B
| $4.26M | ﹤0.01% |
122,699
+170
| +0.1% | +$6.18K |
|
1438
PUT
iShares Russell 2000 ETF
IWM
$82.9B
| $4.23M | ﹤0.01% |
25,000
-81,400
| -77% | -$15M |
|
1439
Jazz Pharmaceuticals
JAZZ
$15.9B
| $4.17M | ﹤0.01% |
26,716
+350
| +1% | +$53.9K |
|
1440
Emergent Biosolutions
EBS
$235M
| $4.13M | ﹤0.01% |
132,927
-118,762
| -47% | -$4.05M |
|
|
ELAT
1441
DELISTED
Elanco Animal Health Incorporated 5.00% Tangible Equity Units
ELAT
| $4.04M | ﹤0.01% |
125,242
-1,554
| -1% | -$58.6K |
|
|
AJRD
1442
DELISTED
Aerojet Rocketdyne Holdings
AJRD
| $3.97M | ﹤0.01% |
97,699
+864
| +0.9% | +$34.9K |
|
|
PRDS
1443
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $3.95M | ﹤0.01% |
1,286,324
-530,235
| -29% | -$3.24M |
|
1444
Owens Corning
OC
$12.2B
| $3.92M | ﹤0.01% |
52,693
+23
| +0% | +$2.03K |
|
1445
First Citizens BancShares
FCNCA
$25.9B
| $3.91M | ﹤0.01% |
5,979
-2
| -0% | -$1.3K |
|
1446
Helmerich & Payne
HP
$4.42B
| $3.88M | ﹤0.01% |
90,148
-4,827
| -5% | -$224K |
|
1447
US Foods
USFD
$23.6B
| $3.87M | ﹤0.01% |
126,034
-2,522
| -2% | -$85.3K |
|
|
CMRC
1448
Commerce.com Inc Series 1
CMRC
$181M
| $3.84M | ﹤0.01% |
236,969
+17,415
| +8% | +$319K |
|
|
OPLN
1449
Openlane
OPLN
$4.36B
| $3.82M | ﹤0.01% |
258,907
-9,095
| -3% | -$143K |
|
1450
GameStop
GME
$8.37B
| $3.82M | ﹤0.01% |
124,932
+8,448
| +7% | +$269K |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.